MetMED: Phase III randomized double-blind placebo-controlled trial of metformin for white matter repair and cognitive recovery in paediatric brain tumour patients
Status: Open | NSW , VIC
Survival rates for paediatric brain tumours has risen to between 50% – 70% over the past 25 years. However, treatment for such aggressive cancers is not without side effects. Radiation treatment in particular leaves many children/adolescents suffering from long-term cognitive impairment and brain injuries impacting learning and behavioural issues.
This 16-week study is to trial the use of the drug Metformin, an oral medication already widely used for diabetes. It will investigate if metformin can promote cognitive recovery and brain growth in children/adolescents treated for medulloblastoma.
Disease stage: Post treatment
Patient age range: 7 Years to 17 Years and 11 months
- National: ANZCHOG
- International: Hospital for Sick Kids, Toronto